TY - JOUR
T1 - Adult Life-Course Trajectories of Lung Function and the Development of Emphysema
T2 - The CARDIA Lung Study
AU - Washko, George R.
AU - Colangelo, Laura A.
AU - Estépar, Raul San José
AU - Ash, Samuel Y.
AU - Bhatt, Surya P.
AU - Okajima, Yuka
AU - Liu, Kiang
AU - Jacobs, David R.
AU - Iribarren, Carlos
AU - Thyagarajan, Bharat
AU - Lewis, Cora E.
AU - Kumar, Rajesh
AU - Han, Mei Lan K.
AU - Dransfield, Mark T.
AU - Carnethon, Mercedes R.
AU - Kalhan, Ravi
N1 - Publisher Copyright:
© 2019
PY - 2020/2
Y1 - 2020/2
N2 - Background: Peak lung function and rate of decline predict future airflow obstruction and nonrespiratory comorbid conditions. Associations between lung function trajectories and emphysema have not been explored. Methods: Using data from the population-based CARDIA Study, we sought to describe the prevalence of visually ascertained emphysema at multiple time points and contextualize its development based upon participant's adult life course measures of lung function. There were 3171 men and women enrolled at a mean age of 25 years, who underwent serial spirometric examinations through a mean age of 55 years. Trajectories for the change in percent-predicted forced expiratory volume in one second (FEV1) were determined by fitting a mixture model via maximum likelihood. Emphysema was visually identified on computed tomographic scans and its prevalence reported at mean ages of 40, 45, and 50 years. Results: We identified 5 trajectories describing peak and change in FEV1: “Preserved Ideal,” “Preserved Good,” “Preserved Impaired,” “Worsening,” and “Persistently Poor.” Ever smokers comprised part of all 5 trajectories. The prevalence of emphysema was 1.7% (n = 46; mean age of 40 years), 2.5% (n = 67; mean age of 45 years), and 7.1% (n = 189; mean age of 50 years). Of those with emphysema at a mean age of 50 years, 18.0% were never smokers. Worsening and poor lung health trajectories were associated with increased odds of future emphysema independent of chronic tobacco smoke exposure (odds ratio 5.06; confidence interval, 1.84-13.96; odds ratio 4.85; confidence interval, 1.43-16.44). Conclusions: Lower peak and accelerated decline in FEV1 are risk factors for future emphysema independent of smoking status.
AB - Background: Peak lung function and rate of decline predict future airflow obstruction and nonrespiratory comorbid conditions. Associations between lung function trajectories and emphysema have not been explored. Methods: Using data from the population-based CARDIA Study, we sought to describe the prevalence of visually ascertained emphysema at multiple time points and contextualize its development based upon participant's adult life course measures of lung function. There were 3171 men and women enrolled at a mean age of 25 years, who underwent serial spirometric examinations through a mean age of 55 years. Trajectories for the change in percent-predicted forced expiratory volume in one second (FEV1) were determined by fitting a mixture model via maximum likelihood. Emphysema was visually identified on computed tomographic scans and its prevalence reported at mean ages of 40, 45, and 50 years. Results: We identified 5 trajectories describing peak and change in FEV1: “Preserved Ideal,” “Preserved Good,” “Preserved Impaired,” “Worsening,” and “Persistently Poor.” Ever smokers comprised part of all 5 trajectories. The prevalence of emphysema was 1.7% (n = 46; mean age of 40 years), 2.5% (n = 67; mean age of 45 years), and 7.1% (n = 189; mean age of 50 years). Of those with emphysema at a mean age of 50 years, 18.0% were never smokers. Worsening and poor lung health trajectories were associated with increased odds of future emphysema independent of chronic tobacco smoke exposure (odds ratio 5.06; confidence interval, 1.84-13.96; odds ratio 4.85; confidence interval, 1.43-16.44). Conclusions: Lower peak and accelerated decline in FEV1 are risk factors for future emphysema independent of smoking status.
KW - Emphysema risk
KW - Lung function trajectory
UR - http://www.scopus.com/inward/record.url?scp=85076626840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076626840&partnerID=8YFLogxK
U2 - 10.1016/j.amjmed.2019.06.049
DO - 10.1016/j.amjmed.2019.06.049
M3 - Article
C2 - 31369720
AN - SCOPUS:85076626840
SN - 0002-9343
VL - 133
SP - 222-230.e11
JO - American Journal of Medicine
JF - American Journal of Medicine
IS - 2
ER -